SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01699698

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Pancreatic Juice Diagnosis From Duodenum

Purpose of this study is to understand the clinical feasibility of duodenal juice diagnosis to screen UICC stage II pancreatic ductal adenocarcinoma patients.

NCT01699698 Pancreatic Adenocarcinoma

1 Interventions

Name: Tumor markers

Description: Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
Type: Other
Group Labels: 1

Test subject

Primary Outcomes

Description: We hypothesized that there is a statistically-significant difference between two cohorts. The cancer marker is S100P.

Measure: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort

Time: 1year

Secondary Outcomes

Description: Based on each analyzing result of pancreatic cancer markers and corresponding final diagnosis, a receiver operating characteristic (ROC) is evaluated. A cut-off is then chosen from this ROC curve to maximize both sensitivity and specificity.1. create an ROC curve using the measured concentrations, 2. set a threshold, 3. report how many patients in each group would are exceeded the threshold. (The rate of exceeded threshold in Test subject group is sensitivity, The rate of 1-(the rate of exceeded threshold in Control group) is specificity.)

Measure: The Sensitivity and Specificity to Detect UICC Stage II Pancreatic Ductal Adenocarcinoma Among All Participants.

Time: 1 year

Purpose: Diagnostic

Allocation: Non-Randomized

Parallel Assignment

There is one SNP


1 S100P

The cancer marker is S100P.. --- S100P ---

HPO Nodes